Vizsgálati helyszín
Synexus Polska Sp. z o.o.
Gdynia, 81-537, LengyelországEU-13 felzárkózó országMég nincs intézményhez kötve
- 20futó vizsgálat
- 16lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 36 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis28 vizsgálat
- 2. fázis7 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Lezárult16 vizsgálat
- Fut, nem toboroz12 vizsgálat
- Toboroz8 vizsgálat
- Fő szponzor
- Ipsen3 vizsgálat
- Pfizer3 vizsgálat
- Alumis Inc2 vizsgálat
- Ascletis Pharma (China) Co. Ltd.2 vizsgálat
- AstraZeneca2 vizsgálat
- és még 23
Futó vizsgálatok
Még nem toboroz
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus
2026-526336-39-00· 3. fázis· Ascletis Pharma (China) Co. Ltd.· Forrás
Toboroz
Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Weight-Related Comorbidities
2026-526172-23-00· 3. fázis· Ascletis Pharma (China) Co. Ltd.· Forrás
Toboroz
SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures
2025-520587-18-00· 2. fázis· Supernus Pharmaceuticals Inc.· Forrás
Fut, nem toboroz
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients with Type 2 Diabetes Mellitus
2025-524514-28-00· 2. fázis· Corxel Pharmaceuticals Inc.· Forrás
Fut, nem toboroz
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
NCT07217015· 2. fázis· Kymera Therapeutics, Inc.· Forrás
Toboroz
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· 3. fázis· AstraZeneca· Forrás
Toboroz
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498· 3. fázis· Incyte Corporation· Forrás
Toboroz
Clinical trial to investigate the efficacy and tolerability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) and placebo on patients with recurrent herpes labialis
2023-510338-10-00· 3. fázis· Laboratorios Ojer Pharma S.L.· Forrás
Fut, nem toboroz
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· 3. fázis· Alumis Inc· Forrás
Fut, nem toboroz
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060· 2. fázis· Ipsen· Forrás
Toboroz
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
2023-505141-48-00· 3. fázis· Akero Therapeutics Inc.· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741· 2. fázis· Nektar Therapeutics· Forrás
Toboroz
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· 3. fázis· Anthos Therapeutics, Inc.· Forrás
Fut, nem toboroz
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578· 2/3. fázis· Sanofi· Forrás
Fut, nem toboroz
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728· 3. fázis· Inventiva Pharma· Forrás
Fut, nem toboroz
A clinical trial to evaluate the safety and effectiveness of MGL-3196 (resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and reduce progression of liver damage and resolve NASH
2024-510626-89-00· 3. fázis· Madrigal Pharmaceuticals Inc.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® Sourced from the European Union in Postmenopausal Women with Osteoporosis
2024-512417-41-00· 3. fázis· Xentria Inc.· Forrás
Lezárult
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06602219· 2. fázis· DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company· Forrás
Lezárult
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
NCT06586112· 3. fázis· Alumis Inc· Forrás
Lezárult
Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis
2023-503790-37-00· 3. fázis· Curateq Biologics Private Limited· Forrás
Lezárult
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864· 3. fázis· Boehringer Ingelheim· Forrás
Lezárult
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06108544· 3. fázis· Takeda· Forrás
Fut, nem toboroz
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
NCT06047444· 3. fázis· Ipsen· Forrás
Fut, nem toboroz
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
NCT06047457· 3. fázis· Ipsen· Forrás
Lezárult
Comparative efficacy, safety, pharmacokinetic, and immunogenicity study of LY06006 and EU-Prolia in postmenopausal women with osteoporosis
NCT05853354· 3. fázis· Shandong Boan Biotechnology Co. Ltd.· Forrás
Lezárult
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05595642· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
NCT05477524· 3. fázis· Pfizer· Forrás
Lezárult
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
NCT05251259· 2. fázis· AstraZeneca· Forrás
Lezárult
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
NCT03989206· 3. fázis· Galderma R&D· Forrás
Lezárult
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
NCT04036435· 3. fázis· Bristol-Myers Squibb· Forrás
Lezárult
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease
2024-511553-22-00· 3. fázis· Celgene International II SARL· Forrás
Lezárult
Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease
2023-510426-33-00· 3. fázis· Celgene International II S.a.r.l.· Forrás
Hibát jelzek